Tretinoin 302-79-4 Vitamin A acid

Min.Order / FOB Price:Get Latest Price

25 Kilogram	FOB Price: USD 1580.0000

25 Kilogram

FOB Price: USD 1580.0000

Min.Order :25 Kilogram
Purity: 99%
Payment Terms : T/T,,MoneyGram,Other

Keywords

Tretinoin Vitamin A acid 302-79-4

Quick Details

Appearance:White crystalline powder
Application:1 Tretinoin is the acid form of vitamin A and is also known as all-trans retinoic acid or ATRA. It is a drug commonly used to treat acne vulgaris and keratosis pilaris. It is available as a cream or g
PackAge:25 kgs/ fiber drum or according to customer's demand
ProductionCapacity:20|Metric Ton|Month
Storage:Store in cool & dry place not freeze., keep away from strong light and heat
Transportation:deliver within1-5 days by DHL,FedEx,AIR,SEA

Superiority:

We warmly welcome customers from at home and abroad to establish cooperation and create a bright future with us together. And leading the way to make health industries heathier, help more people healthy and happy…

Trade Assurance
Get full protection for your orders

100% Product quality protection
100% On-time shipment protection
100% Payment protection

Details:

Tretinoin ; Retinoic acid
CAS Number 302-79-4

Product	Tretinoin (Retinoic acid)	Appearance	yellow or light orange crystalline powder
Cas No.	302-79-4	Molecular formula:	C20H28O2
		Molecular weight :	300.44
Synonyms:	3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid; all-trans-Retinoic acid; Vitamin A acid; Retionoic Acid; Tretinoin (Retionoic Acid); Tretinion ; N,N'-hexane-1,6-diyldiacetamide; retinoic acid; (9cis)-retinoic acid; (11cis,13cis)-7,8-dihydroretinoic acid; 15-oxidoretinal
Specification	98.0~102.0%
Structure
Function	1 Tretinoin is the acid form of vitamin A and is also known as all-trans retinoic acid or ATRA. It is a drug commonly used to treat acne vulgaris and keratosis pilaris. It is available as a cream or gel It is also used to treat acute promyelocytic leukemia. 2 Its success in treating acute promyelocytic leukemia was a major breakthrough in the treatment of this type of leukemia.It works in APL because the majority of cases involve a chromosomal translocation of chromosomes 15 and 17, which causes genetic fusion of the retinoic acid receptor gene to the promyelocytic leukemia gene. This fusion PML-RAR protein is responsibl 3. for preventing immature myeloid cells from differentiating into more mature cells. This block in differentiation is thought to cause leukemia. ATRA acts on PML-RAR to lift this block, causing the immature promyelocytes to differentiate to normal mature blood cells thus decreasing promyelocytes.